FDAnews
www.fdanews.com/articles/81790-metabolic-pharmaceuticals-initiates-recruitment-in-trial-of-obesity-drug

METABOLIC PHARMACEUTICALS INITIATES RECRUITMENT IN TRIAL OF OBESITY DRUG

October 19, 2005

Metabolic Pharmaceuticals initiated the recruitment process for subjects in the low dose Phase II-B human clinical trial of its obesity drug, AOD9604. The trial will be known as the "OPTIONS" study.

Sixteen clinical trial sites in Australia will participate in the study enrolling 480 obese men and women. The sites are located in Melbourne, Sydney, Wollongong, Adelaide, Brisbane, Perth and Canberra. Recruitment has started at one site, and it is anticipated that screening of candidates for enrolment into the study will commence within a few weeks.

A previous Phase II human clinical trial of 12-week AOD9604 daily oral treatment was completed earlier this year, using doses ranging from 1 mg to 30 mg. That trial provided evidence that low doses of AOD9604 produced competitive weight loss in obese subjects, with encouraging indications of improvement in risk factors for diabetes.